Ceviche, appreciate your sentiments. Thanks again for your analysis, I enjoy reading them.
Yes as I have posted recently I believe there is at least some nexus between the FDA pre trial work and what data we present to TGA. I have heard from at least one other that this data might be useful in presenting the dossier, the case, to TGA. Hence, perhaps, the delay along with getting the submission 100% correct.
I can't agree with you more, initial revenues will give a tonne of stability to us as a company and I trust the same is duly considered and bumped up on the priority list now that the exciting roadmap to OA is clearer.
Valuation and Targets, page-345
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.035(12.7%) |
Mkt cap ! $108.4M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 31.0¢ | 27.5¢ | $108.9K | 371.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 17420 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |